Sheedy Patrick, Medarova Zdravka
Department of Health Sciences, CaNCURE Program, Northeastern University Boston, MA 02115, USA.
MGH/MIT/HMS Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School Boston, MA 02129, USA.
Am J Cancer Res. 2018 Sep 1;8(9):1674-1688. eCollection 2018.
Small, non-coding strands of RNA have been identified as a significant player in the pathology of cancer. One of the first miRNAs to be shown as having aberrant expression in cancer was miR-10b. Since the inaugural study on miR-10b, its role as a metastasis promoting factor has been extensively validated. To date, more than 100 studies have been completed on miR-10b and metastasis across 18 cancer types. This immense set of information holds possibilities for novel methods to improve the lives of many. This review outlines what is currently understood of miR-10b's clinical significance, its molecular regulation, and the possible diagnostic and therapeutic methods leveraging miR-10b as a fundamental target in metastatic cancer. Such methods would move us closer to developing a truly individualized therapeutic strategy against cancer and will likely provide unique information about cancer staging, disease outcome, metastatic potential, and ultimately survival.
小的非编码RNA链已被确定为癌症病理学中的一个重要因素。最早被证明在癌症中表达异常的miRNA之一是miR-10b。自关于miR-10b的首次研究以来，其作为转移促进因子的作用已得到广泛验证。迄今为止，已经完成了100多项关于miR-10b与18种癌症类型转移的研究。这大量的信息为改善许多人生活的新方法提供了可能性。本综述概述了目前对miR-10b临床意义、分子调控以及将miR-10b作为转移性癌症基本靶点的可能诊断和治疗方法的理解。这些方法将使我们更接近制定真正个性化的抗癌治疗策略，并可能提供有关癌症分期、疾病预后、转移潜能以及最终生存的独特信息。
